

“REGISTER FOR NSAC MEETING” in the subject line. The deadline for members of the public to register to attend the meeting in-person is Friday, March 24, at 5 p.m. Eastern Time. Members of the public are encouraged to submit registration requests via email in advance of the deadline, as space is limited and will be available on a first-come, first-served basis for those who register in advance. We will note when the limit of in-person attendees has been reached. The meeting will also stream live virtually, and a link will be distributed in advance of the meeting to registrants and also on the Federal Maritime Commission’s website, www.fmc.gov. Please note in the registration request if you would like to attend in person or virtually.

FOR FURTHER INFORMATION CONTACT: Mr. Dylan Richmond, Designated Federal Officer of the National Shipper Advisory Committee, phone: (202) 523-5810; email: drichmond@fmc.gov.

SUPPLEMENTARY INFORMATION:

Background: The National Shipper Advisory Committee is a federal advisory committee. It operates under the provisions of the Federal Advisory Committee Act, 5 U.S.C. App., and 46 U.S.C. chapter 425. The Committee was established on January 1, 2021, when the National Defense Authorization Act for Fiscal Year 2021 became law. Public Law 116-283, section 8604, 134 Stat. 3388 (2021). The Committee provides information, insight, and expertise pertaining to conditions in the ocean freight delivery system to the Commission. Specifically, the Committee advises the Federal Maritime Commission on policies relating to the competitiveness, reliability, integrity, and fairness of the international ocean freight delivery system. 46 U.S.C. 42502(b).

The Committee’s agenda items will include the election of a Chair and Vice Chair. The Committee will also receive an update from Commissioner Carl Bentzel and from each of its subcommittees. The Committee may receive proposals for recommendations to the Federal Maritime Commission and may vote on these recommendations. Any proposed recommendations will be available for the public to view in advance of the meeting on the NSAC’s website, <https://www.fmc.gov/industry-oversight/national-shipper-advisory-committee/>.

Public Comments: Members of the public may submit written comments to NSAC at any time. Comments should be addressed to NSAC, c/o Dylan Richmond, Federal Maritime Commission, 800 North Capitol St. NW,

Washington, DC 20573 or nsac@fmc.gov.

The Committee will also take public comment at its meeting. If attending the meeting and providing comments, please note that in the registration request. Comments are most helpful if they address the Committee’s objectives or their proposed recommendations. Comments at the meeting will be limited to 3 minutes each.

A copy of all meeting documentation, including meeting minutes, will be available at www.fmc.gov following the meeting.

By the Commission.

Dated: March 10, 2023.

William Cody,

Secretary.

[FR Doc. 2023-05313 Filed 3-14-23; 8:45 am]

BILLING CODE 6730-02-P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than March 30, 2023.

A. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President); 1 Memorial Drive, Kansas City, Missouri 64198:

1. *Caroline Berry; the Brooklyn Bass Berry 2019 Irrevocable Trust; the*

Hannah D. Berry 2019 Irrevocable Trust; the Kaylee Doiron Berry 2019 Irrevocable Trust; William L. Berry Jr. and Stacey Berry, as co-trustees of the three preceding trusts; the James Arthur Dilley, Jr. 2019 Irrevocable Trust; the Jarret Blake Dilley 2019 Irrevocable Trust; and Jennifer Berry Dilley and James A. Dilley, as co-trustees of the two preceding trusts, all of Sapulpa, Oklahoma; to join the Berry Family Group, a group acting in concert, to retain voting shares of American Bancorporation, Inc., and thereby indirectly retain voting shares of American Heritage Bank, both of Sapulpa, Oklahoma.

In addition, The Caroline Celen Berry Revocable Trust, Caroline Berry, as trustee, and The Elizabeth Berry Thompson Revocable Trust, Elizabeth Thompson, as trustee, all of Sapulpa, Oklahoma; to join the Berry Family Group, a group acting in concert, to acquire additional voting shares of American Bancorporation, Inc., and thereby indirectly acquire additional voting shares of American Heritage Bank.

Board of Governors of the Federal Reserve System.

Margaret McCloskey Shanks,
Deputy Secretary of the Board.

[FR Doc. 2023-05309 Filed 3-14-23; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of Single-Source Cooperative Agreements To Fund Amhara Regional Health Bureau (ARHB), Ethiopia; Uganda Virus Research Institute (UVRI), Uganda; Hanoi Medical University (HMU), Vietnam; The Cambodian National Institute for Public Health (NIPH), Cambodia; and United Nations Office for Project Services (UNOPS)/The Stop TB Partnership (Stop TB), Headquarters (HQ)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the award of approximately \$20,000,000 for Year 1 funding to ARHB, Ethiopia; approximately \$15,000,000 for Year 1 to UVRI, Uganda; approximately

\$2,000,000 for Year 1 funding to HMU, Vietnam; approximately \$800,000 for Year 1 funding to NIPH, Cambodia; and approximately \$750,000 for Year 1 funding to UNOPS/Stop TB, HQ. These awards will support implementing a comprehensive combination of HIV prevention, monitoring, diagnosis, and treatment systems; emergency preparedness and response; and reduce infectious disease burden in Ethiopia, Uganda, Vietnam, Cambodia and HQ. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT:

Ethiopia: Caroline Ryan, Center for Global Health, Centers for Disease Control and Prevention, P.O. Box 1014, Addis Ababa, Ethiopia, Telephone: 202–663–2684, Email: cgr8@cdc.gov.

Uganda: Ms. Mary Naluguzi, Center for Global Health, Centers for Disease Control and Prevention, U.S. Embassy, Plot 1577 Ggaba Road, P.O. Box 7007, Kampala, Uganda, Telephone: +256–772139151, Email: yrs0@cdc.gov.

Vietnam: Amy Bailey, Center for Global Health, Centers for Disease Control and Prevention, 5th/Floor Tung Shing Building, No. 2, Ngo Quyen Street, Hoan Kiem District Hanoi, Vietnam, Telephone: 84–2439352692, Email: fue8@cdc.gov.

Cambodia: Joyce Neal, Center for Global Health, Centers for Disease Control and Prevention, #80, Samdach Pen Nut Blvd., (289) Sangkat Boeung Kak II, Khan Tuol Kork, Phnom Penh, Cambodia, Telephone: 404–433–0184, Email: jxn4@cdc.gov.

HQ: Rebekah Marshall, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Road, MS US1–1, Atlanta, GA 30329, Telephone: (404) 718–1126, Email: vv2@cdc.gov.

SUPPLEMENTARY INFORMATION:

- *ARHB, Ethiopia:* The single-source award will continue supporting the ARHB in delivering comprehensive HIV/AIDS services to reach HIV epidemic control and other public health priorities.

The ARHB is in a unique position to conduct this work, as it is a government entity established by law with a legal authority and mandated to plan, manage, administer, and coordinate all health-related activities in the Amhara region. It is the uniquely qualified and sole agent of the Ethiopian Government with this mandate and responsibility in the Region.

- *UVRI, Uganda:* The single-source award will support the Ministry of

Health (MOH) with the diagnosis of viral pathogens of public health concern.

UVRI is in a unique position to conduct this work, as it a MOH institution with the mandate to solely provide HIV-related quality assurance and diagnosis of viral pathogens of public health concern for the country.

- *HMU, Vietnam:* The single-source award will support HMU to implement innovations and generate evidence-based models for the National HIV Program and other public health programs by institutionalizing best practices through support for innovation implementation, evaluations, surveillance, and health information systems.

HMU is in a unique position to conduct this work, as it is a parastatal university affiliated to and mandated by the Ministry of Health as Vietnam's primary health workforce training and research institution in the health sector. HMU is the only institution capable of fulfilling the purpose of this NOFO due to its unique position as the sole institution in Vietnam to lead a national network of medical universities, colleges, and secondary medical schools.

- *NIPH, Cambodia:* The single-source award will continue supporting NIPH to fulfill their essential roles to help Cambodia reach and sustain the UNAIDS 95–95–95 goals.

NIPH is in a unique position to conduct this work, as it is the only recognized national reference laboratory authorized by the MOH under Sub-decree 67 ANKr.BK.

- *UNOPS/Stop, HQ:* The single-source award will continue supporting a multi-sectoral approach to re-imagine TB care.

UNOPS/STOP is in a unique position to conduct this work, as it the only organization that has been charged by the World Health Assembly, through Resolution WHA 67.1, to work with the World Health Organization to develop a global investment plan to guide the implementation of the global strategy and targets for TB prevention, care, and control after 2015, that was approved and adopted by all member states.

Summary of the Awards

Recipients: Amhara Regional Health Bureau (ARHB), Ethiopia; Uganda Virus Research Institute (UVRI), Uganda; Hanoi Medical University (HMU), Vietnam; The Cambodian National Institute for Public Health (NIPH), Cambodia; and United Nations Office for Project Services (UNOPS)/The Stop TB Partnership (Stop TB), Headquarters (HQ).

Purpose of the Awards: The purpose of these awards is to support implementing a comprehensive combination of HIV prevention, monitoring, diagnosis, and treatment systems; emergency preparedness and response; and reduce infectious disease burden in Ethiopia, Uganda, Vietnam, Cambodia and HQ.

Amount of the Awards: For ARHB, the approximate year 1 award funding amount is \$20,000,000 in Federal Fiscal Year (FFY) 2023, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. For UVRI, the approximate year 1 award funding amount is \$15,000,000 in Federal Fiscal Year (FFY) 2023, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. For HMU, the approximate year 1 award funding amount is \$2,000,000 in Federal Fiscal Year (FFY) 2023, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. For NIPH, the approximate year 1 award funding amount is \$800,000 in Federal Fiscal Year (FFY) 2023, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. For UNOPS/Stop, the approximate year 1 award funding amount is \$750,000 in Federal Fiscal Year (FFY) 2023, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authorities: Some of these programs are authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

Additionally, for Hanoi Medical University (HMU), Vietnam, and The Cambodian National Institute for Public Health (NIPH), Cambodia are also authorized under sections 301(a) and 307 of the Public Health Service Act, as amended [42 U.S.C. 241(a) and 2421].

Additionally, United Nations Office for Project Services (UNOPS)/The Stop TB Partnership (Stop TB), Headquarters (HQ) does not include 93.067 funds. This program is solely funded under Assistance Listing 93.494 Global Tuberculosis; Statutory Authority: This program is authorized under Section 307 of the Public Health Service Act [42 U.S.C. 2421], as amended and Section 301(a) of the Public Health Service Act [42 U.S.C. 241(a)], as amended.

Period of Performance: September 30, 2023 through September 29, 2028.

Dated: March 9, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05256 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research With Universities in Thailand; Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research with Universities in Thailand; April 12, 2023, 9 a.m.–2:30 p.m., EDT, teleconference, in the original **Federal Register** Notice. The meeting was published in the **Federal Register** on March 2, 2023, Volume 88, Number 41, page 13121.

The meeting is being amended to add a Notice of Funding Opportunity number and should read as follows:

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH20-002, Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; and GH23-003, Conducting Public Health Research with Universities in Thailand.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Mailstop H21-9, Atlanta, Georgia 30329-4027; Telephone: (404) 639-4796; Email: HShoob@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05297 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This meeting is open to the public, limited only by the number of webcast lines available. Time will be available for public comment.

DATES: The meeting will be held on April 12, 2023, from 11 a.m. to 5:30 p.m., EDT, and April 13, 2023, from 11 a.m. to 5 p.m., EDT.

ADDRESSES: This is a virtual meeting. Meeting times are tentative and subject to change. The confirmed meeting times, agenda items, and meeting materials, including instructions for accessing the live meeting broadcast, will be available on the CLIAC website at <https://www.cdc.gov/cliac>. Check the website on the day of the meeting for the web conference link.

FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Senior Advisor for Clinical Laboratories, Division of Laboratory Systems, Office of Laboratory Science and Safety, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia 30329-4027. Telephone: (404) 498-2769; Email: HStang@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Clinical Laboratory Improvement Advisory Committee (CLIAC) is charged with providing scientific and technical advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; the Director, CDC; the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare &

Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine and specific questions related to possible revision of the Clinical Laboratory Improvement Amendments of 1988 (CLIA) standards. Examples include providing guidance on studies designed to improve quality, safety, effectiveness, efficiency, timeliness, equity, and patient-centeredness of laboratory services; revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards on medical and laboratory practice; and the modification of the standards and provision of non-regulatory guidelines to accommodate technological advances, such as new test methods, the electronic transmission of laboratory information, and mechanisms to improve the integration of public health and clinical laboratory practices.

Matters To Be Considered: The agenda will include agency updates from CDC, CMS, and FDA. Presentations and CLIAC discussions will focus on reports from two CLIAC workgroups: the CLIA Regulations Assessment Workgroup and the CLIA Certificate of Waiver and Certificate for Provider-performed Microscopy Procedures Workgroup, and on the laboratory's role in advancing health equity. Agenda items are subject to change as priorities dictate.

Public Participation

It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments pertinent to agenda items.

Oral Public Comment: Public comment periods for each agenda item are scheduled immediately prior to the Committee discussion period for that item. In general, each individual or group requesting to present an oral comment will be limited to a total time of five minutes (unless otherwise indicated). Speakers should email CLIAC@cdc.gov or notify the contact person above (see **FOR FURTHER INFORMATION CONTACT**) at least five business days prior to the meeting date.

Written Public Comment: CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, it is requested that comments be submitted at least five business days prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments should be submitted by email to CLIAC@cdc.gov or to the contact person above. All written comments will be